VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment

BACKGROUND: Targeting tumor vasculature is a strategy with great promise in the treatment of many cancers. However, anti-angiogenic reagents that target VEGF/VEGFR2 signaling have met with variable results clinically. Among the possible reasons for this may be heterogeneous expression of the target...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Patten, Steven G, Adamcic, Una, Lacombe, Kristen, Minhas, Kanwal, Skowronski, Karolina, Coomber, Brenda L
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2010
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3009683/
https://ncbi.nlm.nih.gov/pubmed/21159176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-683
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller